Our CEO, Aileen Lai, participated in a panel discussion on the topic "Identifying the Gaps in Digital Therapeutics (DTx): What is the Industry Missing?"

The discussion addressed various pain points experienced in DTx over the past year and explored strategies to prevent them from recurring. Panelists also reflected on the successes and failures of digital therapeutics to date, discussing how these lessons can advance the field. They examined ways to bridge the gap between digital therapeutics and traditional healthcare systems for seamless integration and debated what it will take to establish DTx as a staple in APAC healthcare systems over the next five years. The panel was moderated by Shwen Gwee, Former VP & Head of Global Digital Strategy at Bristol Myers Squibb, and included Teo Son, Chief Operating Officer at Olive Union; Raju Rhee, Lead Clinical Strategy Innovation & DTx at Dr. Reddy’s Laboratories; Aileen Lai, CEO of HealthBeats® and Vice-Chair of the Digital Health, Start-Ups & SMEs Committee at APACMed; and Ed Deng, CEO & Co-Founder of Health2Sync.


The conference is a multi-stakeholder collaboration, featuring innovative digital therapeuticcompanies, as well as pharma, provider, payer, government, policy and investor perspectives. Expect to hear from leading companies in the industry such as Wellthy Therapeutics, Daiichi Sankyo, Fitterfly, Johnson & Johnson, Dario Health, WELT, EverEx, Dr Reddy’s Laboratories, Samsung and more.


DTx Asia: Singapore will bring together global leaders from every stakeholder group in digital health to catalyze crucial conversations surrounding: reimbursement, adoption, pharma partnerships, investment, design and commercialisation of digital therapeutics.

To read more, please click here.